NasdaqGM - Nasdaq Real Time Price USD

OmniAb, Inc. (OABI)

Compare
3.2200
+0.0100
+(0.31%)
As of 9:39:47 AM EST. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
20,409.0000
34,164.0000
59,077.0000
34,748.0000
23,268.0000
Operating Expense
100,237.0000
103,583.0000
85,725.0000
70,357.0000
48,891.0000
Operating Income
-79,828.0000
-69,419.0000
-26,648.0000
-35,609.0000
-25,623.0000
Net Non Operating Interest Income Expense
3,632.0000
5,055.0000
587.0000
-7.0000
-5.0000
Other Income Expense
-20.0000
1.0000
--
1,266.0000
1,900.0000
Pretax Income
-76,216.0000
-64,363.0000
-26,061.0000
-34,350.0000
-23,728.0000
Tax Provision
-13,198.0000
-13,744.0000
-3,727.0000
-7,308.0000
-6,171.0000
Net Income Common Stockholders
-63,018.0000
-50,619.0000
-22,334.0000
-27,042.0000
-17,557.0000
Diluted NI Available to Com Stockholders
-63,018.0000
-50,619.0000
-22,334.0000
-27,042.0000
-17,557.0000
Basic EPS
-0.62
-0.51
-0.26
-0.24
-0.15
Diluted EPS
-0.62
-0.51
-0.26
-0.24
-0.15
Basic Average Shares
101,195.7500
99,683.0000
85,318.0000
114,820.8590
114,820.8590
Diluted Average Shares
101,195.7500
99,683.0000
85,318.0000
114,820.8590
114,820.8590
Total Operating Income as Reported
-79,828.0000
-69,419.0000
-26,648.0000
-35,609.0000
-25,623.0000
Total Expenses
100,237.0000
103,583.0000
85,725.0000
70,357.0000
48,891.0000
Net Income from Continuing & Discontinued Operation
-63,018.0000
-50,619.0000
-22,334.0000
-27,042.0000
-17,557.0000
Normalized Income
-63,018.0000
-50,619.0000
-22,334.0000
-27,042.0000
-17,557.0000
Interest Income
3,632.0000
5,055.0000
587.0000
--
--
Interest Expense
--
--
--
7.0000
5.0000
Net Interest Income
3,632.0000
5,055.0000
587.0000
-7.0000
-5.0000
EBIT
-79,828.0000
-69,419.0000
-26,648.0000
-34,343.0000
-23,723.0000
EBITDA
-58,917.0000
-49,922.0000
-8,399.0000
-18,091.0000
-10,586.0000
Reconciled Depreciation
20,911.0000
19,497.0000
18,249.0000
16,252.0000
13,137.0000
Net Income from Continuing Operation Net Minority Interest
-63,018.0000
-50,619.0000
-22,334.0000
-27,042.0000
-17,557.0000
Total Unusual Items Excluding Goodwill
291.7550
--
--
--
--
Total Unusual Items
291.7550
--
--
--
--
Normalized EBITDA
-58,917.0000
-49,922.0000
-8,399.0000
-18,091.0000
-10,586.0000
Tax Rate for Calcs
0.0002
0.0002
0.0001
0.0002
0.0003
12/31/2020 - 9/30/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

LGND Ligand Pharmaceuticals Incorporated
117.80
-0.71%
 
TVTX Travere Therapeutics, Inc.
21.17
+0.55%
 
ABOS Acumen Pharmaceuticals, Inc.
1.5900
+1.92%
 
OMER Omeros Corporation
8.81
-0.34%
 
TNGX Tango Therapeutics, Inc.
3.1300
+0.64%
 
RGLS Regulus Therapeutics Inc.
1.0200
+2.00%
 
DYAI Dyadic International, Inc.
1.4750
-1.00%
 
TYRA Tyra Biosciences, Inc.
14.73
+0.14%
 
TRDA Entrada Therapeutics, Inc.
13.47
+0.75%
 
MTVA MetaVia Inc.
1.8120
-8.02%